Integrating Plasma Metabolomics, Network Pharmacology, and Experimental Validation to Investigate the Action Mechanism of Qiangxin Lishui Prescription in Chronic Heart Failure
Biomedical Chromatography · 2025
DOI: 10.1002/bmc.6065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomedical Chromatography, 2025. Verfasst von Yong Jiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China. Hauptthemen laut MEDLINE: Drugs, Chinese Herbal, Heart Failure, Network Pharmacology, Metabolomics. Die Arbeit nennt 30 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Youth Medical Innovation Research Project of China, Nanjing Medical University.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
The high mortality rate of chronic heart failure (CHF) makes it a primary battlefield in the field of cardiovascular diseases. Qiangxin Lishui Prescription (QLP) is a traditional Chinese medicine (TCM) prescription used clinically for treating CHF, but its underlying mechanism remains unclear. This study integrated plasma metabolomics, network pharmacology, and experimental validation to reveal the pharmacological effects of QLP and its potential mechanism of anti‐CHF. Using ultra‐high‐performance liquid chromatography combined with quadrupole time‐of‐flight mass spectrometry (UPLC‐Q/TOF‐MS/MS), 119 absorbed prototype compounds of QLP were identified from rat plasma. By applying network pharmacology and molecular docking techniques, a QLP absorption components–target–CHF network was constructed. The IL6/JAK/STAT3 signaling pathway is likely critical to QLP's therapeutic effect on CHF. A CHF mouse model was established using aortic ligation surgery to investigate the regulation of the IL6/JAK/STAT3 pathway by QLP in CHF mice. Network pharmacology analysis and in vivo experimental data indicate that QLP alleviates myocardial injury and inflammatory response in CHF mice by modulating the IL6/JAK/STAT3 pathway, significantly improving cardiac function. This presents a promising therapeutic strategy for CHF treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou, China.
- Department of Pharmacy, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou, China.
ORCID-Profile: Yong Jiang, Qin Wang, Linwei Chen
Förderung
- National Natural Science Foundation of China
- Youth Medical Innovation Research Project of China
- Nanjing Medical University
- Science and Technology Support Project of Taizhou
Zitieren
APA
Jiang, Y., Ji, W., Lu, Y., Wang, Q., & Chen, L. (2025). Integrating Plasma Metabolomics, Network Pharmacology, and Experimental Validation to Investigate the Action Mechanism of Qiangxin Lishui Prescription in Chronic Heart Failure. Biomedical Chromatography. https://doi.org/10.1002/bmc.6065
Vancouver
Jiang Y, Ji W, Lu Y, Wang Q, Chen L. Integrating Plasma Metabolomics, Network Pharmacology, and Experimental Validation to Investigate the Action Mechanism of Qiangxin Lishui Prescription in Chronic Heart Failure. Biomedical Chromatography. 2025. doi:10.1002/bmc.6065
BibTeX
@article{Jiang2025,
author = {Jiang, Yong and Ji, Wenjun and Lu, Ying and Wang, Qin and Chen, Linwei},
title = {Integrating Plasma Metabolomics, Network Pharmacology, and Experimental Validation to Investigate the Action Mechanism of Qiangxin Lishui Prescription in Chronic Heart Failure},
journal = {Biomedical Chromatography},
year = {2025},
doi = {10.1002/bmc.6065}
}
EUVIMED